PL1673472T3 - Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki - Google Patents

Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki

Info

Publication number
PL1673472T3
PL1673472T3 PL04765830T PL04765830T PL1673472T3 PL 1673472 T3 PL1673472 T3 PL 1673472T3 PL 04765830 T PL04765830 T PL 04765830T PL 04765830 T PL04765830 T PL 04765830T PL 1673472 T3 PL1673472 T3 PL 1673472T3
Authority
PL
Poland
Prior art keywords
genetic polymorphisms
il1a
hepatotoxicity
predict drug
induced hepatotoxicity
Prior art date
Application number
PL04765830T
Other languages
English (en)
Inventor
Karen Mccullough
Curt Douglas Wolfgang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL1673472T3 publication Critical patent/PL1673472T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04765830T 2003-10-06 2004-10-05 Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki PL1673472T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50897203P 2003-10-06 2003-10-06
EP04765830A EP1673472B1 (en) 2003-10-06 2004-10-05 Use of genetic polymorphisms to predict drug-induced hepatotoxicity
PCT/EP2004/011123 WO2005040415A1 (en) 2003-10-06 2004-10-05 Use of genetic polymorphisms to predict drug-induced hepatotoxicity

Publications (1)

Publication Number Publication Date
PL1673472T3 true PL1673472T3 (pl) 2011-07-29

Family

ID=34520003

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04765830T PL1673472T3 (pl) 2003-10-06 2004-10-05 Zastosowanie polimorfizmów genetycznych do przewidywania hepatotoksyczności indukowanej przez leki

Country Status (14)

Country Link
US (1) US20070248955A1 (pl)
EP (1) EP1673472B1 (pl)
JP (1) JP4979382B2 (pl)
CN (1) CN1882705A (pl)
AT (1) ATE498021T1 (pl)
AU (1) AU2004283234B2 (pl)
BR (1) BRPI0415299A (pl)
CA (1) CA2540760C (pl)
DE (1) DE602004031352D1 (pl)
ES (1) ES2361018T3 (pl)
MX (1) MXPA06003827A (pl)
PL (1) PL1673472T3 (pl)
PT (1) PT1673472E (pl)
WO (1) WO2005040415A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10262107B1 (en) * 2013-03-15 2019-04-16 Bao Tran Pharmacogenetic drug interaction management system
CN108949947B (zh) * 2017-05-25 2022-06-28 上海市预防医学研究院 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点
CN116239665B (zh) * 2023-03-10 2024-08-23 山东大学 Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
US6214819B1 (en) * 1998-11-23 2001-04-10 Novartis Ag Method for treating ocular neovascular diseases
AU2001294228A1 (en) * 2000-10-12 2002-04-22 Takeda Chemical Industries Ltd. Benzimidazole compounds, process for producing the same and use thereof
GB0212648D0 (en) * 2002-05-31 2002-07-10 Immunoclin Lab Ltd Treatment with cytokines

Also Published As

Publication number Publication date
EP1673472A1 (en) 2006-06-28
AU2004283234B2 (en) 2007-08-30
PT1673472E (pt) 2011-05-12
JP2007512231A (ja) 2007-05-17
CN1882705A (zh) 2006-12-20
EP1673472B1 (en) 2011-02-09
MXPA06003827A (es) 2006-06-14
DE602004031352D1 (de) 2011-03-24
CA2540760A1 (en) 2005-05-06
WO2005040415A1 (en) 2005-05-06
ES2361018T3 (es) 2011-06-13
JP4979382B2 (ja) 2012-07-18
ATE498021T1 (de) 2011-02-15
US20070248955A1 (en) 2007-10-25
AU2004283234A1 (en) 2005-05-06
CA2540760C (en) 2013-01-08
BRPI0415299A (pt) 2006-12-26

Similar Documents

Publication Publication Date Title
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
AU2003285866A1 (en) Methods for assessing efficacy of chemotherapeutic agents
EP3467123A3 (en) Methods and compositions of molecular profiling for disease diagnostics
IL182519A0 (en) Methods and compositions for predicting drug responses
EP1985715A3 (en) ESR1 and cervical cancer
EP1492440B8 (en) A new method for the diagnosis and prognosis of malignant diseases
MX2007007568A (es) Variantes geneticas de vkorci que predicen la sensibilidad a la warfarina.
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
MX2009008461A (es) Variantes geneticas que contribuyen a riesgo de cancer de prostata.
EP1565608A4 (en) WASHING MACHINE, CONDUCTIVITY SENSOR PROVIDED IN THE WASHING MACHINE AND METHOD OF CONTROLLING THE SAME
DE602005004461D1 (de) Verfahren und Vorrichtung für das Verringern der Leistungsaufnahme von IRDA ermöglichten Handsets, indem ein IRDA Port dynamisch ein- und ausgeschaltet wird
MY142988A (en) Novel aminobenzophenone compounds
WO2006071466A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
UA90706C2 (ru) Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
SG158133A1 (en) Method for reversing multiple resistance in animal cells
DE50311974D1 (de) Kühlplatte für metallurgische öfen
MX2008001428A (es) Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos.
WO2008144599A3 (en) Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
DK1498129T3 (da) Anvendelse af adenovirusser, muteret i VA generne, til cancerbehandling
MX2009004382A (es) Variaciones geneticas asociadas con tumores.
PT1673472E (pt) Utiliza??o de polimorfismos gen?ticos na predi??o de hepatotoxicidade induzida por f?rmacos
SI1753512T1 (sl) Tetrahidropiridotiofeni
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof